Sera is a women’s health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera provides pivotal information during pregnancy to physicians, designed to help improve the health of their patients, and to reduce the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the prediction of preterm birth risk and other complications of pregnancy. Sera’s PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

TechLab, Inc. develops, manufactures, and distributes rapid non-invasive intestinal diagnostics. It focuses on enteric disease and microbiology of the intestinal tract, and scope of study includes markers of intestinal inflammation, the toxins of Clostridium difficile, amebiasis, and vaccine development. It offers diagnostic tests for colitis, parasitology, intestinal inflammation, and Shiga toxins of enterohemorrhagic E. coli. The company was founded by Tracy Wilkins in 1989 and is headquartered in Blacksburg, VA.

IntelliGeneScan, Inc. operates as a biotech company focused on disease diagnostics using gene expression analysis. The company engages in development and commercialization of colon cancer diagnostic test. IntelliGeneScan, Inc. was founded in 2006 and is based in Santa Rosa, California.

Manufactures cancer diagnostics systems and products

DKFZ Deutsche Krebsforschungszentrum is a German private company that operates as a cancer research center.

Ikfe Institut f��r Klinische Forschung und Entwicklung GmbH is a private company headquartered in Mainz, Germany, that engages in research and development in the field of natural sciences, engineering, agricultural sciences and medicine. It was founded in 1998.

Ridge Diagnostics is a neurodiagnostic company offering its proprietary first-in-class blood test for Major Depressive Disorder (MDD) through its CLIA-certified laboratory in North Carolina. Based upon it’s proprietary Human Biomarker Library and it’s Biomarker Hyper-Map™ technology platform, Ridge Diagnostics has developed multi-variant biological marker assays and diagnostic algorithms to manage the treatment of depression

Cleveland HeartLab, Inc. operates as a holding and clinical reference laboratory company. It focuses on novel molecular biomarker technologies and the creation of proprietary diagnostic tests. The company was founded by Jake Orville and Marc S. Penn in 2009 and is headquartered in Cleveland, OH.

Cardiac Pacemakers, Inc.(CPI), doing business as Guidant Cardiac Rhythm Management, manufactured implantable cardiac rhythm management devices, such as pacemakers and defibrillators. It also sold insulin pumps controlled by microprocessors and various equipments to regulate heart rhythm. In addition, Cardiac Pacemakers, Inc. developed therapies for the treatment of irregular heartbeats. The company was founded in 1971 and is based in St. Paul, Minnesota. Cardiac Pacemakers, Inc. operates as a subsidiary of Boston Scientific Corporation.

Singulex, Inc., a biotechnology company, develops and commercializes direct molecular detection technology solutions. Its solutions enable life science researchers and clinicians to understand and manage disease. The company develops biomarker diagnostic systems that can detect and quantify normal and abnormal protein biomarkers. It is conducting pilot studies to validate Erenna BioAssay System, a digital molecule detection platform, which detects and quantifies molecule biomarkers in clinical samples. The company also offers various custom assay services, such as pilot study services, assay prototyping, assay characterization, and assay validation. The company was formerly known as BioProfile Corporation and changed its name to Singulex, Inc in September 2003. Singulex is based in Hayward, California

Apitope International NV develops therapeutic vaccines. It operates as a bio-pharmaceutical company that engages in developing peptide therapies. The firm specializes on the discovery and development of revolutionary disease modifying therapies for treating autoimmune and allergic diseases, including multiple sclerosis, and Graves�� disease, FVIII intolerance and uveitis. The company was founded by David Wraith in 2002 and is headquartered in Diepenbeek, Belgium.

Vermilion, Inc. is an American private company located in Boulder, CO. The firm operates as an advertising agency specializes in audience research, brand development, web design & development services. It was founded by Bob Morehouse. Susan Touchette Aust is the current CEO, occupying that position since 1992.\nThe company says this about itself: Vermilion is a full-service, creative agency based in Boulder, Colorado, that provides distinctive and effective solutions exclusively to organizations that make a positive impact. As a Certified B Corporation, the agency is focused on helping purpose-driven brands grow and make a difference, supporting organizations advancing health and well-being, and connecting conservation and recreation in outdoor and environmental brands. Vermilion is also a Public Benefit Corporation, a specific type of corporation that allows for public benefit and social impact to be a charter purpose in addition to traditional corporate goals.

MUbio Products B.V. (MUbio) is a privately owned Dutch biotech company, founded in 2000 by Dr. R. Vleugels and Prof. Dr. F. Ramaekers. The company originated as a spin out from the Department of Molecular Cell Biology of the Maastricht University.\nMUbio produces high quality reagents and bioassays for cell biology and biomedical research. MUbio's product portfolio includes an increasing number of well-characterized antibodies for oncology research, produced in an ISO certified laboratory.\nMUbio’s partnered and proprietary R&D projects focus on the identification and validation of cancer biomarkers, development of lung cancer diagnostic kits & research and development of a lung cancer vaccine.

Biohit Oyj engages in the development, manufacture, and market of diagnostic tests and analysis systems. It also offers acetaldehyde binding products, monoclonal antibodies, and instruments. The company was founded by Osmo Suovaniemi in 1988 and is headquartered in Helsinki, Finland.

Octave’s Precision Care Solution is the first-of-its-kind that accurately and objectively measures, and helps manage, complex and high-cost neurodegenerative diseases, starting with multiple sclerosis. Octave developed the first and only multivariate blood test to measure MS disease activity, enhanced MRI analytics and protocols, and a digital clinical program with Octave MS care partners to provide continuity of care. Provider: The solution provides neurologists with a longitudinal and holistic perspective of the patient along with comprehensive and actionable insights, enabling more confident and informed care decisions. Payer: The integrated and multi-dimensional approach allows payers to reduce total cost of care by optimizing healthcare medications and utilization (hospitalizations, ER visits, MRIs, labs). Pharma: Octave enables pharma to optimize the entire lifecycle of drug discovery & development as well as clinical trials and post marketing with real world evidence. Through purposeful problem solving and innovative technologies, Octave’s platform generates, analyzes and combines data to create a new paradigm of MS care, leading to improved patient outcomes.

Metamark Genetics, Inc is a life science company dedicated to the development of prognostic and predictive diagnostic tests that will enable personalized treatment planning for cancer patients, improved outcomes, and reduced healthcare costs. Metamark was founded in November, 2007 to transform cancer diagnosis and treatment by developing pioneering diagnostic products based on its Prognosis Determinantsâ„¢ Platform. Prognosis Determinantsâ„¢ are functionally validated genetic elements at the core of cancer progression across many major cancer types. Based on pioneering research in melanoma by Dr. Lynda Chin at the Dana-Farber Cancer Institute and Harvard Medical School, the Prognosis Determinantsâ„¢ were first discovered as functionally active drivers of metastasis that confer poor outcome. Prognosis Determinantsâ„¢ have been shown to be relevant to a broad spectrum of different tumors and can stratify patients according to their overall and metastasis-free survival.

Biocartis SA, a molecular diagnostics company, develops diagnostics technology platform for multiplexed detection of bio-analytes. It focuses on integrated molecular and immunodiagnostics based on its proprietary micro-technology platform. The company develops and licenses a series of technologies to build a diagnostics platform for multiplexed detection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules. Its products are used for various applications, including analysis of bio-molecules associated with risks factors, early detection, staging, treatment selection, and monitoring of a disease. Biocartis SA was founded in 2007 and is based in Lausanne, Switzerland.

SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.